Leukapheresis for CAR-Therapy Manufacturing
Condition(s)
Leukemia Lymphoma
Leukemia Lymphoma
Age Group
0-9 years 10-17 years 18-26 years 27 years and older
0-9 years 10-17 years 18-26 years 27 years and older
Phase(s)
Other
Other
Trial Summary & Details
Ages: 4 Years to 30 Years
Condition: Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Condition: Leukemia, Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Background:
Leukapheresis is a procedure to separate and collect white blood cells. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy. CAR-T therapy may be offered to people when their cancer comes back. The collected T-cells are used to make a special version of T-cells called CARs. Researchers want to collect these cells from people who may become eligible for a CAR T-cell study in the future.
Objective:
To identify people who have a high likelihood to benefit from CAR T-cell therapy early in their disease course and collect and store a T-cell product.
Eligibility:
People ages 4-30 with a form of leukemia or lymphoma that has not been cured by standard therapy
Status
Recruiting
Location(s)
National Institutes of Health (NIH) Clinical Center, Bethesda, MD
Sponsor/Collaborators:
National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC)
Sponsor/Collaborators:
National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC)